Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The 'New' Vifor Pharma: Focused On Specialty Pharma

Executive Summary

With a new hyperkalemia therapy nearing EU markets and its injectable iron product showing strong sales growth, Switzerland’s global specialty pharma company Vifor Pharma has been able to upgrade its financial guidance for 2017.

You may also be interested in...



Going Solo Suits Vifor And Its Hopes For Two Blockbusters

Enjoying its independence from Galenica, Switzerland’s third-largest pharmaceutical company believes that Ferinject and Veltassa will help it achieve sales of over CHF2bn by 2020.

AstraZeneca's Lokelma To Join Veltassa In Hyperkalemia Sector

The treatment of hyperkalemia in Europe in patients with chronic kidney disease or chronic heart failure looks set to become more vibrant, with AstraZeneca's Lokelma likely to join Vifor Pharma's Veltassa in the marketplace.

Pipeline Watch: Phase III Starts With Rimegepant, ARQ087 And SGX942

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC099298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel